Hemispherx (HEB) fails to win FDA panel backing for Ampligen efficacy

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/15/2026

1. SPY
2. PYPL
3. JPM
4. GS
5. AMZN

6. MSFT
7. SPCX
8. PNR
9. USO
10. GOOGL

December 20, 2012 4:29 PM EST

Price: $1.80 --0%

Overall Analyst Rating:
SELL (= Flat)

Hemispherx Biopharma, Inc. (NYSE: HEB) fails to win FDA panel backing for Ampligen efficacy.

FDA, Trader Talk

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!